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Abstract
Background: Current guidelines recommend dual anti-platelet therapy, aspirin and clopidogrel, for patients treated
with drug-eluting stent for coronary heart disease. In a few small trials, addition of cilostazol on dual anti-platelet
therapy (triple anti-platelet therapy) showed better late luminal loss. In the real-world unselected patients with
coronary heart disease, however, the effect of cilostazol on platelet reactivity and ischemic vascular events after
drug-eluting stent implantation has not been tested. It is also controversial whether there is a significant
interaction between lipophilic statin and clopidogrel.
Methods/Design: CILON-T trial was a prospective, randomized, open-label, multi-center, near-all-comer trial to
demonstrate the superiority of triple anti-platelet therapy to dual anti-platelet therapy in reducing 6 months’ major
adverse cardiovascular/cerebrovascular events, composite of cardiac death, nonfatal myocardial infarction, target
lesion revascularization and ischemic stroke. It also tested whether triple anti-platelet therapy is superior to dual
anti-platelet therapy in inhibiting platelet reactivity in patients receiving percutaneous coronary intervention with
drug-eluting stent. Total 960 patients were randomized to receive either dual anti-platelet therapy or triple anti-
platelet therapy for 6 months and also, randomly stratified to either lipophilic statin (atorvastatin) or non-lipophilic
statin (rosuvastatin) indefinitely. Secondary endpoints included all components of major adverse cardiovascular/
cerebrovascular events, platelet reactivity as assessed by VerifyNow P2Y12 assay, effect of statin on major adverse
cardiovascular/cerebrovascular events, bleeding complications, and albumin-to-creatinine ratio to test the
nephroprotective effect of cilostazol. Major adverse cardiovascular/cerebrovascular events will also be checked
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any medium, provided the original work is properly cited.at 1, 2, and 3 years to test the ‘legacy’ effect of triple anti-platelet therapy that was prescribed for only 6 months
after percutaneous coronary intervention.
Discussion: CILON-T trial will give powerful insight into whether triple anti-platelet therapy is superior to dual anti-
platelet therapy in reducing ischemic events and platelet reactivity in the real-world unselected patients treated
with drug-eluting stent for coronary heart disease. Also, it will verify the laboratory and clinical significance of drug
interaction between lipophilic statin and clopidogrel.
Trial Registration: National Institutes of Health Clinical Trials Registry (ClinicalTrials.gov identifier# NCT00776828).
Background
Current guidelines recommend at least 6 months of dual
anti-platelet agents, consisting of aspirin and a thieno-
pyridine, after percutaneous coronary intervention (PCI)
and ideally, 1 year of both drugs [1]. However, some
patients experience acute thrombotic events, the inci-
dence of which has been diverse from less than 1% to
3% [2,3] even with good adherence to this dual anti-
platelet therapy (DAT), and also, late restenotic compli-
cation after PCI. In addition, as interventional cardiolo-
gists face more and more complex lesions, the risk of
ischemic events, including cardiac events, may tend to
rise. These problems raise the issue to whether there are
effective additional methods or drugs to prevent
ischemic complications.
Cilostazol is a selective phosphodiesterase-3 (PDE-3)
inhibitor, which has various effects including vasodila-
tory, anti-platelet and partially, anti-inflammatory effect.
Several investigators have focused on cilostazol as one
of the candidate drugs that can reduce ischemic events
after PCI. Inspite of the fact that cilostazol is metabo-
lized by CYP 3A [4] and to a lesser degree 2C19 [5], the
same pathway as that of clopidogrel, cilostazol was sug-
gested to be effective in reducing platelet reactivity in
vitro [6] and also, efficacious and safe in reducing
thrombotic complications in the real world [7]. Also,
several studies have suggested that cilostazol successfully
and safely reduces restenosis rate after PCI [8-11]. In a
meta-analysis, cilostazol has shown to be consistently
helpful in reducing binary angiographic restenosis and
repeat revascularization. But these data were derived
mainly from the BMS era [12]. Data from a few rando-
mized trials have suggested that cilostazol reduces late
luminal loss also in drug-eluting stents (DES) [10,13].
But, these trials were underpowered to see whether
cilostazol reduces the ultimate core endpoint of clinical
trials, major adverse cardiac events (MACE) or major
adverse cardiovascular/cerebrovascular events (MACCE).
And the restricted inclusion criteria of the previous ran-
domized trial cannot answer to the question whether
cilostazol would be effective also in a routine clinical
practice. These previous reports call for a large, rando-
mized, controlled study to investigate whether cilostazol
can really reduce MACE/MACCE after PCI in a real-
world practice and also, for an extensive follow-up of
these patients to see whether the effects persists in the
long-term, as in a recent pooled analysis [14].
Additionally, there have been numerous questions as
to whether there are significant interaction between clo-
pidogrel and lipophilic statin and whether such interac-
tion can be overcome by the addition of cilostazol.
Although data on this matter is controversial but some-
what been in favor of being no significant in vivo inter-
action between clopidogrel and lipophilic statin [15], the
interpretation and application of these data have been
restricted by the unrandomized/unstratified manner of
the studies [16-18] and non-prospective collection of the
data [19]. Also, although the pleiotrophic effect of cilos-
tazol in renal function has been demonstrated in some
animal experiments [20,21], whether this holds true for
humans have never been investigated.
I no r d e rt op r o v i d ead e f i n i t ea n s w e rt ot h ea b o v e
questions, we planned the ‘Influence of CILostazol-based
triple anti-platelet therapy ON Ischemic Complication
after drug-eluting stenT implantation (CILON-T)’ study.
In this study, we compared the efficacy and safety of
triple anti-platelet therapy (TAT), composed of aspirin,
clopidogrel and cilostazol, with the conventional DAT by
evaluating MACCE and platelet reactivity in an unse-
lected population of patients receiving PCI with DES for
coronary heart disease (CHD) in real-world practice. In
addition, we would like to get answers for the issues
whether lipophilic statin-clopidogrel interaction would
influence the patient outcome and whether cilostazol can
overcome such interaction, using atorvastatin (Lipitor®,
Pfizer) dependent on cytochrome P450-3A4 (CYP3A4)
for metabolism versus rosuvastatin (Crestor®, AstraZe-
neca) independent from CYP3A4.
Methods/Design
Study objectives, hypothesis and design
The primary objective of this study was to compare the
efficacy of TAT with DAT in reducing 6 months’
MACCE after PCI in those with documented CHD. The
working hypothesis of this trial was ‘TAT is superior to
DAT in reducing 6 months’ MACCE, the composite of
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Page 2 of 8cardiac death, nonfatal myocardial infarction (MI),
ischemic stroke and target lesion revascularization
(TLR) in CHD patients receiving PCI with DES’.T h e
trial also addressed whether TAT is superior to DAT in
reducing platelet reactivity and also, whether there is
any clinical effect of statin-clopidogrel interaction on
MACCE according to the type of statin. The protocol of
the trial has been registered at http://www.clinicaltrials.
gov (NCT00776828) and a brief flowchart of the whole
study is summarized in Figure 1. The endpoints are
summarized in Appendix 1.
Patient population
Patients at least 18 years of age who had typical
ischemic symptoms or positive stress test and a native
coronary lesion (≥50% diameter stenosis by visual esti-
mation on coronary angiogram and reference dia-
meter≥2.5 mm)) were included in this study. Five high-
volume centers in Korea participated and enrolled the
patients in this multicenter, open-label, prospective, ran-
domized trial. There were nearly no angiographic limita-
tions about the number of lesions, vessels, location of
lesions or their length, to investigate the effect of cilos-
tazol in the real-world setting. The following patients
were excluded from the study; cardiogenic shock; expli-
cit side effect or contraindications to anti-platelet agents
including cilostazol; concomitant treatment with any
other anti-platelet agent or anticoagulant other than the
study drugs; current user of cilostazol before the entry
of study. The detailed inclusion and exclusion criteria
are summarized in Appendix 2.
Randomization and interventions
All patients received 300 mg aspirin and 300~600 mg
clopidogrel loading before the procedure unless the
patient had been taking these medications for at least 1
Figure 1 Flowchart of the enrolled patients
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receive either conventional DAT or TAT and also, ran-
domly stratified to take equipotent doses of either ator-
vastatin 20 mg or rosuvastatin 10 mg per day before the
interventional procedure. The patients were also strati-
fied according to the enrolling medical centers/hospitals.
A loading dose of cilostazol (Otsuka Korea) 200 mg was
given immediately before the procedure. Random alloca-
tion of the patients was done via a Web-based compu-
terized program separately managed at medical research
collaboration center, Seoul National University Hospital.
PCI was done according to the standard technique and
the decision of the pre-dilatation and use of glycopro-
tein IIb/IIIa inhibitors were up to the operator’s discre-
tion. The target lesion/vessel was designated as the first
lesion/vessel that was intervened. Platelet reactivity was
measured by using the Ultegra Rapid Platelet Function
Assay (VerifyNow® Aspirin and VerifyNow® P2Y12 assay,
Accumetrics Inc., San Diego, California, USA) immedi-
ately before discharge.
After enrollment and index PCI procedure, clinical
follow-up was planned at 1, 3, 6 months and all patients
were recommended follow-up coronary angiography at
6 months according to local clinical practice. Platelet
reactivity was also measured at 6 months after index
procedure. The investigators were urged to follow the
patients, either by office visits or by telephone contacts
as necessary. Patient adherence to the study drug was
checked at every outpatient visit and the decision of the
drug discontinuation was always discussed and checked
under the physician’s recommendation.
Outcome measures
The primary endpoint of this study was the rate of
MACCE, a composite ischemic vascular event following
PCI, including cardiac death, nonfatal MI, TLR and
ischemic stroke at 6 months in the DAT and TAT
group. The key secondary endpoints defined a priori are
- P2Y12 reaction unit (PRU) as assessed by Verify-
Now® P2Y12 assay
- Cardiac death, nonfatal MI, TLR, target vessel
revascularization (TVR), stent thrombosis and
ischemic stroke
- MACCE according to the type of statin and its
interaction with clopidogrel
- Bleeding, as defined according to the TIMI bleed-
ing classifications [22], major bleeding defined by
t h ep r e s e n c eo fa tl e a s t1o ft h ef o l l o w i n g :i n t r a c r a -
nial bleeding (documented with magnetic resonance
imaging, computed tomography, any other examina-
tion or autopsy), or clinically overt bleeding resulting
in a 5 g/dL decrease in hemoglobin value (or, when
hemoglobin values were not available, a 15%
decrease in hematocrit).
- Angiographic outcome, such as late luminal loss,
binary restenosis at 6 months’ follow-up angiography
- Albumin-to-creatinine ratio
Statistical Analysis
Sample size calculation
To test the hypothesis that TAT is superior to DAT in
reducing MACCE at 6 months after PCI, based on the
previous outcome data [10,13,23], we assumed that
MACCE rate in DAT and TAT group would be 10%
and 5% respectively. Using a superiority design, an esti-
mated total of 960 patients was needed to ensure a
power of at least 80% to detect a 5% difference in the
composite of ischemic vascular events between the two
anti-platelet therapy groups using a two-sided t-test,
with a sampling ratio of DAT:TAT at 1:1, bilateral risk
set at 5% and drop-out rate estimated to be 10%.
Statistical Analyses
A l la n a l y s i sw i l lb ed o n eb yi n t e n t i o n - t o - t r e a tm e t h o d
(all patients analyzed as part of their assigned treatment
group). However, per protocol (patients analyzed as part
of their assigned group only if they actually received
their assigned treatment) and as-treated analysis will
also be performed solely for descriptive comparison.
The primary endpoint of 6 months’ MACCE will be
analyzed using c
2-test on an intention-to-treat analysis.
The hypothesis will be evaluated based on a superiority
testing. The clinical secondary endpoints will also be
tested based on c
2-test, similarly as primary endpoint
testing. The endpoints will be analyzed in pre-specified
subgroups, which includes the presence of diabetes mel-
litus, long lesions (lesion length≥28 mm), small vessel
lesions (lesion diameter < 2.75 mm), age and sex. Also,
most importantly, post-hoc analysis of MACCE accord-
ing to the type of statin given (atorvastatin vs. rosuvasta-
tin) will be done. Analysis of platelet function will be
tested using repeated ANOVA method with the Bonfer-
roni’s correction.
Continuous variables will be presented as mean ± SD
a n dc o m p a r e dw i t ht h eu s eo fu n p a i r e dS t u d e n t ’st - t e s t
or in the case of non-normal distribution, Mann-Whit-
ney U test. Categorical variables will be summarized as
number or percentages and compared with c
2 or Fish-
er’s exact test, as appropriate. Survival curves using all
available follow-up data will also be constructed for
time-to-event variables using Kaplan-Meier estimates
and compared by log-rank test. A p-value < 0.05 will be
considered statistically significant.
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Executive Committee
The Executive Committee, constituted of the study
chairperson and the principal investigators of the inves-
tigating centers, approved the final trial design and pro-
tocol issued to the Data and Safety Monitoring Board
(DSMB) and the clinical sites. In addition, it was also
responsible for reviewing the results, determining the
adjudication of the publication, and selection of second-
ary projects by members of the Steering Committee.
Data Safety Monitoring Board (DSMB)
An independent DSMB, composed of general and inter-
ventional cardiologists, and a biostatistician abided by
the applicable regulatory guidelines and did not partici-
pate in the trial. The DSMB committee reviewed the
safety data from this study and made recommendations,
based on safety analyses of unanticipated device effects
(UADEs), serious adverse events (SAEs), protocol devia-
tion, device failures, and follow-up reports. In addition
to the scheduled DSMB meetings, that were determined
prior to the initiation of the study, the board convened
a meeting at any time if safety problems became an
i s s u e .T h eD S M Bw e r er e s p o nsible for recommending
the Executive Committee to modify or stop the study if
there were any safety or compliance issue. However, the
final decisions regarding study modifications rested with
the Executive Committee. Cumulative safety data were
reported to the DSMB and reviewed on an ongoing
basis throughout enrollment and follow-up to ensure
safety of the patients. Every effort was made to allow
the DSMB to conduct an unbiased review of the
patients’ safety information. All DSMB reports were
made available to the appropriate agencies upon request
but were otherwise remained strictly confidential. Prior
to the DSMB’s first review of the data, the DSMB char-
ter was drafted. The plan defined the stopping rules for
stopping the trial for safety. The first meeting of the
DSMB was requested for discussion of the protocol and
an understanding of all the protocol elements. The
DSMB developed a consensus understanding of all trial
endpoints and definitions used in the event adjudication
process.
Clinical Event Adjudication Committee (CEAC)
The Clinical Events Adjudication Committee (CEAC)
was comprised of interventional and non-interventional
cardiologists who were not participants in the study.
The CEAC was responsible for the development of spe-
cific criteria used for categorization of clinical events
and clinical endpoints in the study, which were based
on protocol. At the onset of the trial, the CEAC estab-
lished clear rules stating the minimum amount of data
required, and the algorithm followed in order to classify
a clinical event. All members of the CEAC were blinded
to the primary results of the trial and met regularly to
review and adjudicate all clinical events in which the
required minimum data was available. The Committee
also reviewed and ruled on all deaths that occurred
throughout the trial.
Data Coordination and Site Management
Data coordination and site management services were
performed by the Clinical Trials Center at Seoul
National University Hospital.
Ethical approval
This study was approved by institutional review board of
Seoul National University Hospital.
Discussion
With the advent of various coronary balloons, stents and
wires, PCI is widely used and accepted not only to
improve angina symptoms but also to reduce cardiovas-
cular mortality, albeit in the setting of acute coronary
syndrome. Although the development of DES has been
a major leap in the field of interventional cardiology in
reducing recurrent ischemic events, it has been manda-
tory to use DAT for at least 6 months and preferably, 1
year to prevent stent thrombosis (ST). Even under the
protection of DAT, some subsets of patients suffer from
cardiovascular ischemic events including ST, necessitat-
ing search for new methods to prevent future ischemic
cardiovascular events.
Rationale of cilostazol use to prevent ischemic
cardiovascular events
Cilostazol is a selective PDE3 inhibitor that prevents
degradation of intracellular cAMP into 5’-AMP. It has
various action mechanisms on various cells. For exam-
ple, cilostazol has been shown to inhibit the expression
of platelet activation markers, such as p-selectin [24]
and glycoprotein IIb/IIIa receptors, thus inhibiting plate-
let aggregation and adhesion [25]. It has also been
proved that cilostazol enhances endothelial function by
nitric oxide production [26] and reduces various inflam-
matory responses in endothelial cells [27]. Furthermore,
cilostazol is pro-apoptotic to vascular smooth muscle
cells and ultimately reduces neointimal formation [28].
Taken together, cilostazol is a drug that may prevent
ST, restenosis and improve endothelial function
theoretically.
Previous reports of cilostazol use in PCI and the
rationale of the CILON-T trial
With the potential benefit of cilostazol on vascular func-
tion in vitro, there have been several previous efforts to
prove the efficacy of cilostazol in patients undergoing
PCI. For example, the efficacy of cilostazol has been
tested in patients who received percutaneous translum-
inal coronary angioplasty (PTCA) [29], bare-metal stent-
ing [7,9,30] and also in those at high risk of events after
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the above mentioned trials utilizing adjunctive cilostazol
has reported an appraisal of cilostazol for inhibiting
neointimal hyperplasia [12]. However, very few trials
have effectively nor properly addressed the issue of
whether cilostazol can reduce MAC(C)E, the ultimate
concern of all trials. Especially, this issue has never been
addressed in the DES era nor in the situation of real-
world practice, urging a need for a randomized clinical
trial to answer this question.
Issues sought in the CILON-T trial
In addition to the primary endpoint of whether TAT
would be superior to DAT in reducing the ischemic vas-
cular events after PCI, CILON-T trial is planned to
assess several issues that remains to be answered. The
issue of whether laboratory benefits are directly con-
nected with clinical outcomes will be sought. Specifi-
cally, there have been papers demonstrating that PRU
levels predicted adverse cardiovascular events in high
risk patients [31-33] and that cilostazol reduced the
average level of platelet activation in patients with cor-
onary heart disease [6] and also, PRU level [34]. How-
ever, racial difference is one factor that can influence
the platelet reactivity [35] and there remains a paradox
between the higher level of PRU and lower rate of
thrombotic events after DES implantation in Asians.
Simply compared, the rate of stent thrombosis involving
more than 3,000 patients around 1.5 years after DES
implantation is 1.9% in Europeans [36] while 0.77% in
Japanese [2]. In this CILON-T trial, we can get valuable
information whether cilostazol-induced reduction of
PRU levels would lead to beneficial clinical outcomes.
It is also expected to shed light on whether non-
CYP3A4-metabolized statin is superior to CYP3A4-
metabolized statin in terms of MAC(C)E and if so,
whether cilostazol would be effective in reducing this
difference. In vitro studies have persistently suggested
that the effect of clopidogrel would be reduced by con-
comitant use of lipophilic statin [37,38] but large in vivo
studies do not show trend toward detrimental effect of
these types of statin [16-18,39]. However, these in vivo
results come from observational registry data or post-
hoc analysis of randomized clinical trials. Therefore, our
data would add additional information to clopidogrel-
statin interaction issue and also, if any, a new finding on
the effect of cilostazol in this drug interaction.
In conclusion, we still do not know whether TAT is
superior to DAT in reducing MACCE after DES implan-
tation for coronary heart disease in the unselected real-
world patients. Furthermore, whether cilostazol-induced
PRU level reduction will turn out to improve clinical
outcomes has never been elucidated. We hope to
address these issues in the CILON-T trial where we
enrolled a large unselected population of patients trea-
ted with DES for significant coronary heart disease.
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Appendix
Appendix 1. Endpoints of CILON-T trial
Primary endpoints
MACCE (composite of cardiac death, nonfatal MI, TLR and ischemic stroke)
Secondary endpoints
Individual composites of MACCE
Platelet reactivity unit as assessed by Ultegra Rapid Platelet Function Assay
(VerifyNow®)
MACCE according to the type of statin and its interaction with clopidogrel
Bleeding complications, as defined by TIMI classification
Angiographical outcome at 6 months’ angiographical follow-up (late luminal
loss, binary restenosis)
Albumin-to-creatinine ratio
Appendix 2. Enrollment criteria for CILON-T trial
General inclusion criteria
At least 18 years of age
Able to confirm and understand the risk, benefits and treatment alternatives
of receiving cilostazol and
also to provide written informed consent
Significant coronary artery stenosis (≥50% by visual estimate)
Evidence of myocardial ischemia (stable angina, acute coronary syndrome
with evidence of myocardial
ischemia by symptomatic assessment or by stress test)
Adequate candidate for percutaneous coronary intervention (PCI)
General exclusion criteria
Known hypersensitivity or contraindications to heparin, aspirin, clopidogrel,
contrast media, cilostazol or statin
Previous anti-platelet user (excluding aspirin or clopidogrel) or warfarin user
Female of childbearing potential, unless a recent pregnancy test is negative,
who possibly plans to become pregnant in the near future
History of bleeding diasthesis or coagulopathy or baseline
thrombocytopenia (PLT count < 120,000/μL)
Chronic kidney disease (defined as Cr≥2.0 mg/dL or on dialysis)
Poor left ventricular systolic function (LVEF < 30%)
Significant liver disease (defined as AST/ALT > 3×UNL or liver cirrhosis Child
B/C)
Significant dyslipidemia (total cholesterol≥350 mg/dL or triglyceride≥840
mg/dL)
Age > 80
Chronic alcohol use or drug abuser
Angiographic inclusion criteria
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Page 6 of 8Target lesion(s) located in a native coronary artery with visually estimated
diameter≥2.5 mm
Target lesion(s) amenable to PCI (left main, bifurcation and chronic total
occlusion lesion included)
Angiographic exclusion criteria
Target lesion(s) with ISR
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